Processa Pharmaceuticals Announces Key Leadership Appointments
Key Highlights
- ➤Processa names four executives across operations, research, development and business operations
- ➤July acquisition of Vidya and private placement raised approximately $200 million
- ➤VT-7208 advancing toward Phase 2 programs in food allergy, CSU and multiple sclerosis
- ➤FDA cleared VT-7208’s IND for planned Phase 2 chronic spontaneous urticaria study
- ➤Processa signed research collaboration and exclusive option agreement with Generian Pharmaceuticals
Expert Statements
Sheila Gujrathi, M.D., Executive Chair of the Processa Board of Directors
“As we advance our Bruton’s tyrosine kinase inhibitor VT-7208 across multiple immune-mediated diseases and continue to expand our pipeline, we are excited to be building the leadership team for Processa’s next stage of growth.”
Sheila Gujrathi, M.D., Executive Chair of the Processa Board of Directors
“Greg is an accomplished biotechnology executive who will play a central role in leading the company forward, while Craig, Ashley, and Mike bring deep and complementary experience across research, development and operations.”
Sheila Gujrathi, M.D., Executive Chair of the Processa Board of Directors
“Craig also brings a unique connection to our lead program as one of the scientists who helped invent VT-7208.”
Sheila Gujrathi, M.D., Executive Chair of the Processa Board of Directors
“Together, this is a highly experienced team with the capabilities to move quickly, execute with discipline and deliver on the opportunity ahead.”
VERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced key leadership appointments to support the Company’s next phase of growth: * Gregory J. Flesher, Chief Operating Officer * Craig Coburn, Ph.D., Executive Vice President, Head of Research * Ashley Hall, J.D., Executive Vice President, Development * Michael P. Cruse, Executive Vice President, Business Operations “As we advance our Bruton’s tyrosine kinase inhibitor VT-7208 across multiple immune-mediated diseases and continue to expand our pipeline, we are excited to be building the leadership team for Processa’s next stage of growth,” said Sheila Gujrathi, M.D., Executive Chair of the Processa Board of Directors. “Greg is an accomplished biotechnology executive who will play a central role in leading the company forward, while Craig, Ashley, and Mike bring deep and complementary experience across research, development and operations. Craig also brings a unique connection to our lead program as one of the scientists who helped invent VT-7208. Together, this is a highly experienced team with the capabilities to move quickly, execute with discipline and deliver on the opportunity ahead.”
Get started
Create a free account to read the full story.